Expanded Approval for Targeted Radiotherapy in Prostate Cancer
The FDA has approved the radiotherapy lutetium Lu 177 vipivotide tetraxetan for certain patients with metastatic prostate cancer. The...
Progress Against Cancer
The FDA has approved the radiotherapy lutetium Lu 177 vipivotide tetraxetan for certain patients with metastatic prostate cancer. The...
The FDA has approved the multi-kinase inhibitor cabozantinib for certain adult and pediatric patients with rare neuroendocrine tumors. The...
The FDA has approved a PD-1 blockade treatment regimen for certain patients with advanced stomach and gastroesophageal cancer. The...
The FDA has approved a new combination regimen for certain patients with esophageal cell squamous cell carcinoma. The U.S....
The FDA has approved a CSF1 small molecule inhibitor for certain patients with symptomatic tenosynovial giant cell tumor. The...
The FDA has approved the antibody-drug conjugate brentuximab vedotin, plus lenalidomide and rituximab, for certain cases of pretreated large...
The FDA has approved a new MEK inhibitor for certain patients with symptomatic neurofibromatosis type 1. The U.S. Food...
The FDA has approved fam-trastuzumab deruxtecan-nxki for certain HER2-low or HER2-ultralow breast cancers. The U.S. Food and Drug Administration...
The FDA approved treosulfan and fludarabin for patients with hematologic disorders prior to stem cell transplantation. The U.S....
The FDA has issued its first approval for datopotamab deruxtecan-dlnk, a targeted therapy, for certain types of breast cancer. ...